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Abstract—The study was aimed to investigate the effect of technologically treated diclofenac (release-
active dilutions of diclofenac (RAD of diclofenac)) on anti-inﬂammatory activity of diclofenac in
carrageenan-induced rat paw edema model. Ninety male Wistar albino rats (6–8 weeks) divided into
nine groups (n=10) were used. Anti-inﬂammatory activity was assessed at 1, 2, 3, 4, and 6 h after
subplantar injection of carrageenan (0.1 ml of a 1 % solution in normal saline). Diclofenac alone was
studied at 5 and 20 mg/kg, RAD of diclofenac alone at 7.5 ml/kg and their combination at 5 and
7.5 ml/kg, respectively. Diclofenac reduced (p<0.05 at least) paw edema at all time points. RAD of
diclofenac enhanced (p<0.05) anti-inﬂammatory effect of diclofenac (5 mg/kg) at 2, 4, and 6 h on
concurrent and at 2 and 4 h on sequential administration. Moreover at 2 h, anti-inﬂammatory effect of
combination treatment reached values comparable to those of diclofenac (20 mg/kg). In conclusion,
RAD of diclofenac enhanced anti-inﬂammatory effect of diclofenac.
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INTRODUCTION
Diclofenac belongs to nonsteroidal anti-inﬂammatory
class of drugs (NSAIDS) and it is the most well-known
NSAID globally [1]. Diclofenac produces analgesic, anti-
pyretic, and anti-inﬂammatory effects and is widely used for
the treatment of moderate pain and inﬂammation, which are
common symptoms of various diseases [1]. Diclofenac
effect is mediated by inhibition of cyclooxygenase (COX),
an enzyme converting arachidonic acid into prostaglandins
(PGs), thromboxanes, and prostacyclins. Due to adverse
effects, diclofenac should be used in at the lowest dose and
for the shortest term possible [1]. Thus, many attempts were
made to develop an approach of combining diclofenac with
different agents which could increase sensitivity to
diclofenac and decrease its dose [2–11].
One such approach might consist in using release-
active therapeutics with their effect mediated by speciﬁcally
processed ultradilutions of the starting substance [12]. The
efﬁcacy of such technologically treated compounds, release-
active dilutions (RAD), was shown for both antibodies and
chemical substances [12–14]. RAD corresponds to a new
class of therapeutics which demonstrated speciﬁc modulat-
ing activity [12]. Modifying effects of RADwere discovered
in 1996when it was established that combined application of
prednisolone in therapeutic doses and its RAD to experi-
mental animals alleviated toxic side effects and tended to
enhance its anti-inﬂammatory activity [15]. Further studies
conﬁrmed this phenomenon. It was shown that modulating
action of RAD of phenazepam signiﬁcantly potentiated
anxiolytic and anticonvulsant effects of therapeutic doses of
phenazepam in Vogel conﬂict test and in rats with corazol-
induced seizures, both after prior or simultaneous adminis-
tration [16]. Combination of RAD of haloperidol and
therapeutic doses of haloperidol signiﬁcantly increased
psychotropic neuroleptic effect of conventional doses of
the drug administered preliminarily or simultaneously [17].
In addition, RAD of haloperidol served to reduce signiﬁ-
cantly cataleptogenic side effect of haloperidol.
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Based upon the beneﬁcial effects of RAD technol-
ogy, the present study in carrageenan-induced paw edema
test was designed to develop and investigate potential
novel approach in altering anti-inﬂammatory activity of
diclofenac by combining it with its release-active form.
MATERIALS AND METHODS
Experimental Animals
The experimental design and use of animals were
approved by Institutional Animal Ethics Committee
(IAEC proposal no. IAEC/20/181) of Dabur Research
Foundation, Ghaziabad, India. Animals (90 male Wistar
albino rats (Rattus norvegicus) weighing 178–295 g (6–
8 weeks)) were supplied by Animal Facility, Dabur
Research Foundation and housed ﬁve animals per cage
at 21.4-23 °C and relative humidity between 52 and 58 %.
They had access to food and water ad libitum and were
exposed to alternate 12 h light and dark cycles.
Drugs and Chemicals
Carrageenan (Cat. No. 22049), diclofenac sodium
salt (Cat. No. D6899), and sodium carboxymethyl
cellulose (Na-CMC; Cat No. 419273-100G) were pur-
chased from Sigma-Aldrich, USA. Normal saline (sodi-
um chloride injection IP 0.9 %; w/v) was obtained from
Shri Krishnakeshav Lab. Ltd. (Ahmedabad, India).
Preparation of diclofenac release-active dilutions
RAD of diclofenac is a clear solution for oral use
manufactured by ООО “NPF “MATERIA MEDICA
HOLDING”, Russia, using diclofenac sodium salt (Sig-
ma-Aldrich, Cat No. D6899) as a starting substance.
Release-active dilutions were manufactured using routine
methods described in the European Pharmacopoeia (6th
Edition, 2007) as described previously [12]. All ultrahigh
dilutions were prepared in glass vials. Starting substance
(diclofenac sodium salt) was dissolved in a solvent
(ethanol–water solution) and shaken for 1 min to produce
the ﬁrst centesimal (C1) dilution. All subsequent dilutions
consisted of one part of the previous dilution and 99 parts of
solvent (ethanol–water solution for intermediate dilutions
and distilled water for preparation of the ﬁnal dilution) with
succession between each dilution. Thus, RADof diclofenac
contain release-active dilutions of diclofenac, which was
diluted up to receiving the mixture of ﬁnal dilutions C12+
C30+C200. Solutions were prepared in sterile conditions
avoiding direct intense light and stored at room tempera-
ture. Quality of RAD of diclofenac was conﬁrmed by
quality control of diclofenac substance fulﬁlled in accor-
dance with the requirements of the European Pharmaco-
poeia monograph ‘Diclofenac sodium’ (01/2008:1002),
quality control of incoming materials and excipients, as
well as usage of validated manufacturing process.
In case of placebo, solvent (ethanol–water solution)
was used to prepare ultrahigh dilutions instead of
diclofenac powder using the same method described
above. RAD of diclofenac and placebo were coded by
manufacturer and used blinded in the study.
Experimental Design
In the present study, we investigated the anti-
inﬂammatory activity of RAD of diclofenac alone or in
combination with diclofenac using carrageenan-induced
paw edema test according to the modiﬁed method of
Winter et al. [18]. Male Wistar rats were selected for the
study based on available literature [19–22]. The animals
were randomized based on their body weight and divided
into nine different groups consisting of 10 animals each.
Rats were given a subcutaneous (s.c.) injection of
carrageenan (0.1 ml of 1 % solution in normal saline)
into the plantar side of the left hind paw. The paw was
marked with ink at the level of lateral malleolus. The paw
volume was measured up to the mark using digital
plethysmometer (LE 7500, Panlab, Harvard Apparatus)
before (−1 h) and at 1, 2, 3, 4, and 6 h after injection of
carrageenan for all the animals (Fig. 1). Paw edema
volume was calculated by subtracting −1 h paw volume
from the respective paw volumes at 1, 2, 3, 4, and 6 h.
Similarly, percentage of anti-inﬂammatory activity was
calculated for each animal using the following formula:
paw edema of control (in milliliter)−paw edema of test
(in milliliter)/paw edema of control (in milliliter)×100 %.
Test Drug Treatment Schedule
For groups 1 and 2 (concurrent administration),
diclofenac powder was dissolved in RAD of diclofenac
(water solution) or placebo (water solution), respectively, in
order to achieve the ﬁnal concentration of diclofenac in the
solutions equal to 5 mg/kg. For groups 3 and 4 (sequential
administration), rats received 7.5 ml/kg of RAD of
diclofenac or placebo, respectively, via gavage. After
10 min dosing, diclofenac was administered at the dose of
5 mg/kg. For groups 5 and 6, rats received 7.5 ml/kg of
RAD of diclofenac or placebo, respectively, via gavage. For
groups 7 and 8, rats received diclofenac at the dose levels of
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5 and 20 mg/kg, respectively. Group 9 rats received 7.5 ml/
kg of 0.25 % Na-CMC solution via gavage. All diclofenac
formulations were prepared in 0.25 % Na-CMC. Similarly,
all the formulations were administered to the respective
group of animals at the dose volume of 7.5 ml/kg. The
groups, the drug treatment and carrageenan administration
are summarized in Table 1.
Statistical Analysis
The data are expressed as mean±standard error of
mean (SEM) for each group. Data of control group and the
groups receiving test drugs were analyzed by one-way
analyses of variance (ANOVA). In post hoc analysis, mean
response of two groups was compared using Dunnett’s t
test. Data of the groups receiving test drugs were analyzed
by generalized estimating equations. Calculation was
carried out by GENMOD. A value of p<0.05 were
considered statistically signiﬁcant.
RESULTS
Subcutaneous injection of carrageenan in rats led to a
time-dependent gradual enhancement of paw volume with
Fig. 1. The experimental design. A Combination of RAD of diclofenac (7.5 ml/kg) and diclofenac (5 mg/kg; diclofenac was administered concurrently
with RAD of diclofenac), G2 combination of placebo (7.5 ml/kg) and diclofenac (5 mg/kg; diclofenac was administered concurrently with placebo), G5
RAD of diclofenac (7.5 ml/kg), G6 placebo (7.5 ml/kg), G7 diclofenac (5 mg/kg), G8 diclofenac (20 mg/kg), G9 control (0.25 % Na-CMC solution;
7.5 ml/kg). B G3 Combination of RAD of diclofenac (7.5 ml/kg) and diclofenac (5 mg/kg) (diclofenac was administered after 10 min of RAD of
diclofenac), G4 combination of placebo (7.5 ml/kg) and diclofenac (5 mg/kg; diclofenac was administered after 10 min of placebo).
Table 1. Test Drug Formulations and Carrageenan Treatment Schedule
Groups Test drug treatment Dose (p.o.) Carrageenan administration (min)a
G1 RAD of diclofenac+diclofenac (CA) 7.5 ml/kg+5 mg/kg 60
G2 Placebo+diclofenac (CA) 7.5 ml/kg+5 mg/kg 60
G3 RAD of diclofenac+diclofenac (SA) 7.5 ml/kg+5 mg/kg 50
G4 Placebo+diclofenac (SA) 7.5 ml/kg+5 mg/kg 50
G5 RAD of diclofenac 7.5 ml/kg 60
G6 Placebo 7.5 ml/kg 60
G7 Diclofenac 5 mg/kg 60
G8 Diclofenac 20 mg/kg 60
G9 Control (0.25 % Na-CMC solution) 7.5 ml/kg 60
CA concurrent administration (diclofenac was administered concurrently with the test drug), SA sequential administration (diclofenac was administered
after 10 min of the test drug)
a Time duration between treatment administration and carrageenan subcutaneous injection
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maximal values at 3, 4, and 6 h (Table 2). Diclofenac at 5
and 20 mg/kg considerably (p<0.05 at least) reduced paw
edema at all time points after carrageenan injection as
compared to control. Diclofenac produced maximum
inhibition in paw edema at 2 h after 5 mg/kg dose and 3 h
for 20 mg/kg dose and paw swelling signiﬁcantly (p<0.01)
reduced by 56.17±3.89 and by 71.82±6.53%, respectively
(Table 2, Fig. 2).
Administration of RAD of diclofenac (7.5 ml/kg) for
1 h prior to carrageenan injection signiﬁcantly (p<0.01)
inhibited carrageenan-induced edema in rat paw at the 2 and
6 h time points as compared to control. There was a
reduction in paw volume at the 3 and 4 h time points as well
but the difference was insigniﬁcant (Table 2, Fig. 3). In
contrast, administration of placebo did not prevent enhance-
ment of paw volume at any time points (Table 3, Fig. 4).
Co-administration of RAD of diclofenac with low
dose of diclofenac (5 mg/kg) enhanced inhibitory effect
of diclofenac (Table 2, Fig. 3). Anti-inﬂammatory effect
of a combination exceeded (p<0.05) that of diclofenac
alone (5 mg/kg) at 2, 4, and 6 h in concurrent
administration and at 2 and 4 h in sequential administra-
tion. More importantly, at 2-h time point, anti-inﬂamma-
tory effect of the combinations reached values
comparable to group of diclofenac alone at high dose
(20 mg/kg). In addition, the effect of individual treatment
with diclofenac (5 mg/kg) was signiﬁcantly lower (p<
0.05 at least) than the one of diclofenac at high dose
(20 mg/kg) at all time points. However, combined
treatment with diclofenac (5 mg/kg) and RAD of
diclofenac produced greater inhibition in paw edema,
which was not signiﬁcantly different from the effect of
diclofenac at high dose (20 mg/kg) at 2 and 4 h after
carrageenan injection for concurrent administration and at
2, 4, and 6 h after sequential administration. Co-
administration of placebo did not have any effect on
inhibitory activity of diclofenac (5 mg/kg) despite the fact
of no signiﬁcant difference in anti-inﬂammatory activity
at 1 and 2 h after carrageenan injection as compared to
diclofenac 20 mg/kg for concurrent and sequential
administration, respectively (Table 3, Fig. 4).
DISCUSSION
Our primary aim was to assess whether anti-
inﬂammatory activity of diclofenac could be enhanced
by RAD of diclofenac and, therefore, allow to decrease
the dose of diclofenac or duration of its administration.
Among many methods aimed at screening of anti-
inﬂammatory drugs, one of the most useful techniques is
based upon ability of such agents to inhibit edema
produced in rat hind paw after injection of 1 % carra-
geenan. It has been widely used as a simple and reliable
model to assess anti-inﬂammatory activity of various
agents [19–25]. Also, inhibition of carrageenan-induced
inﬂammation has been shown to be highly predictive of
anti-inﬂammatory drug activity in human inﬂammatory
disease and doses of NSAIDs in this model correlate well
with effective dose in patients [26]. In addition, this
model allows to detect orally active anti-inﬂammatory
agent particularly in acute phase of inﬂammation [27].
The paw volume is measured before and after injection of
carrageenan and the paw volume of treated animals is
compared to the controls. Any substance having ability to
reduce paw volume in this model potentially acts as an
anti-inﬂammatory agent by inhibiting synthesis of release
of inﬂammatory mediators.
Table 2. Effect of RAD of Diclofenac on Paw Edema at Different Time Points
Groups Treatment
Mean paw edema (ml)±SEM at different time points
1 h 2 h 3 h 4 h 6 h
G1 RAD of diclofenac+diclofenac
(5 mg/kg) (CA)
0.14±0.01*@@ 0.17±0.02**# 0.33±0.05**@@ 0.34±0.04**# 0.37±0.03**#@@@
G3 RAD of diclofenac+diclofenac
(5 mg/kg) (SA)
0.14±0.02*@@ 0.16±0.03**# 0.31±0.05**@@@ 0.31±0.05**# 0.31±0.05**
G5 RAD of diclofenac 0.15±0.02 0.40±0.05** 0.58±0.05 0.51±0.04 0.46±0.03**
G7 Diclofenac (5 mg/kg) 0.14±0.02*@@ 0.25±0.02**@ 0.36±0.02**@@@ 0.43±0.03**@@@ 0.42±0.04**@@@
G8 Diclofenac (20 mg/kg) 0.08±0.02** 0.17±0.03** 0.18±0.04** 0.25±0.05** 0.25±0.03**
G9 Control 0.21±0.02 0.56±0.02 0.65±0.02 0.64±0.03 0.64±0.02
CA concurrent administration, SA sequential administration, SEM standard error of mean
*p<0.05, **p<0.01 in comparison with control at the same time points (Dunnett’s t test)
# p<0.05, ## p<0.01, ### p<0.001 in comparison with diclofenac (5 mg/kg) at the same time points (Generalized Estimating Equations)
@ p<0.05, @@ p<0.01, @@@ p<0.001 in comparison with diclofenac (20 mg/kg) at the same time points (generalized estimating equations)
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Suitability of this model in terms of assessment of
diclofenac anti-inﬂammatory activity as well as possibil-
ity to increase diclofenac-induced anti-inﬂammatory
response or maintain its efﬁcacy but with reduction of
adverts effects has been the subject of several experiments
[2–11]. Also, diclofenac and/or its metabolites were
shown to have a tendency for reaching higher concentra-
tion in inﬂamed footpads in the carrageenan-injected
animals [28] inhibiting COX activity. COX-2 isoform,
selective target for diclofenac [29], is the rate limiting
enzyme for the synthesis of PGs, important mediators of
inﬂammation [30, 31]. Also, COX-2 is known to play a
role in PGs production under inﬂammatory conditions as
well [32, 33]. Development of edema after carrageenan
injection is believed to be biphasic and mediators operate
in sequence to produce inﬂammatory response [30, 34].
The early phase of inﬂammation (0–2 h after injection of
carrageenan) is acknowledged by the role of mediators
like histamine, 5-hydroxytryptamine and bradykinin,
while the late accelerating phase (2–6 h postcarrageenan
injection) has been attributed to elevated production of
PGs, oxygen-derived free radicals, and production of
COX-2 [20, 21, 27].
In this study, anti-inﬂammatory effect of diclofenac
was conﬁrmed as it reduced carrageenan-induced edema
in rat paw in a dose-dependent manner. Diclofenac
showed maximum anti-inﬂammatory activity at 2 and
3 h for the low (5 mg/kg) and high doses (20 mg/kg),
respectively, and maintained the activity until the last time
point analyzed. These ﬁndings are in line with the
available literature suggesting the effects of diclofenac
in late phase (2–6 h) of inﬂammatory response [6–11].
Co-administration of RAD of diclofenac (7.5 ml/kg)
and diclofenac (5 mg/kg) produced comparable anti-
inﬂammatory activity to that of high dose of diclofenac
(20 mg/kg) at 2-h time point. Among the methods studied,
sequential administration revealed marginal advantage
over concurrent administration. Sequential administration
of RAD of diclofenac and diclofenac resulted in >50 %
anti-inﬂammatory activity at 2 h and at subsequent time
points studied. This clearly indicates that RAD of
diclofenac effectively enhances anti-inﬂammatory effects
of diclofenac (5 mg/kg) at all time points at and after 2 h.
Ability of RAD of diclofenac to enhance efﬁcacy of
diclofenac and improve its safety has been already
conﬁrmed in previous studies [12, 35]. Thus, anti-
nociceptive effect of diclofenac, as shown in behavioral
test of acetic acid seizures, was signiﬁcantly improved,
when it was administrated in combination with RAD of
diclofenac [12]. According to Petrov VI et al., RAD of
diclofenac decrease toxicity of diclofenac by increasing
LD50 value and reducing duration of intoxication symp-
Fig. 2. Anti-inﬂammatory activity (%, mean±SEM) of diclofenac (5 and 20 mg/kg) given orally 60 min before carrageenan injection.
5Efﬁcacy of Release-Active Dilutions of Diclofenac
Fig. 3. Anti-inﬂammatory activity (%, mean±SEM) of diclofenac (5 and 20 mg/kg), RAD of diclofenac (7.5 ml/kg) and their combination in carrag-
eenan-induced rat paw edema model. Combination of RAD of diclofenac (7.5 ml/kg) and diclofenac (5 mg/kg) were given orally 60 min before
carrageenan injection (CA concurrent administration) or sequentially starting with RAD of diclofenac administration (7.5 ml/kg) followed by diclofenac
administration (5 mg/kg) in 10 min time interval (SA sequential administration).
Table 3. Effect of Placebo on Paw Edema at Different Time Points
Groups Treatment
Mean paw edema (ml)±SEM at different time points
1 h 2 h 3 h 4 h 6 h
G2 Placebo+diclofenac (5 mg/kg) (CA) 0.12±0.02** 0.23±0.03**@ 0.35±0.05**@@@ 0.42±0.06**@@@ 0.39±0.04**@@@
G4 Placebo+diclofenac (5 mg/kg) (SA) 0.12±0.01**@@ 0.20±0.03** 0.31±0.04**@@ 0.41±0.03**@@@ 0.43±0.04**@@@
G6 Placebo 0.20±0.03 0.47±0.03 0.60±0.03 0.56±0.04 0.52±0.04
G7 Diclofenac (5 mg/kg) 0.14±0.02*@@ 0.25±0.02**@ 0.36±0.02**@@@ 0.43±0.03**@@@ 0.42±0.04**@@@
G8 Diclofenac (20 mg/kg) 0.08±0.02** 0.17±0.03** 0.18±0.04** 0.25±0.05** 0.25±0.03**
G9 Control 0.21±0.02 0.56±0.02 0.65±0.02 0.64±0.03 0.64±0.02
CA concurrent administration, SA sequential administration, SEM standard error of mean
* p<0.05, ** p<0.01 in comparison with control at the same time points (Dunnett’s t test)
# p<0.05, ## p<0.01, ### p<0.001 in comparison with diclofenac (5 mg/kg) at the same time points (generalized estimating equations)
@ p<0.05, @@ p<0.01, @@@ p<0.001 in comparison with diclofenac (20 mg/kg) at the same time points (generalized estimating equations)
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toms and the period of rehabilitation in a model of acute
toxicity [35]. Therefore, the results of the current study
are in line with the previous ﬁndings.
The distinct mechanism mediating enhanced effect of
diclofenac by RAD of diclofenac is still under investiga-
tion. However, long-term experience of development
target-based therapeutics containing release-active dilu-
tions [12, 36] and also investigation of two regimes of
RAD of diclofenac and diclofenac administration (co-
administration and sequential administration) provided us
with the basis to make a conclusion on the initial target for
RAD of diclofenac. For therapeutics containing release-
active dilution of different substances that are currently on
market and under development, the ability to modify
substance-associated targets was shown [12, 36]; it means
that in case of RAD of diclofenac, COX is one of the
targets. This assumption found conﬁrmation in the results
of this study. RAD of diclofenac possessed anti-inﬂamma-
tory activity itself which means that this agent could inhibit
inﬂammation-related processes. Sequential administra-
tion showed more pronounced results vs. concurrent
administration showing that RAD of diclofenac-in-
creased sensitivity of diclofenac targets, i.e., COX.
Another support for potential involvement of COX as a
target of RAD of diclofenac is that enhanced diclofenac
activity was shown on the late phase of inﬂammation
with COX dominating. Obviously, suggestion on
mechanism of RAD of diclofenac effect resulting from
this study should be the subject of further research
work.
Fig. 4. Anti-inﬂammatory activity (%, mean±SEM) of diclofenac (5 and 20 mg/kg), placebo (7.5 ml/kg), and their combination in carrageenan-induced
rat paw edema model. Combination of placebo (7.5 ml/kg) and diclofenac (5 mg/kg) were given orally 60 min before carrageenan injection (CA
concurrent administration) or sequentially starting with placebo administration (7.5 ml/kg) followed by diclofenac administration (5 mg/kg) in 10-min
time interval (SA sequential administration).
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Previous ﬁndings and the results of the current study
provide encouraging basis for simultaneous use of RAD
of diclofenac and diclofenac. Particularly, based on
additive anti-inﬂammatory activity achieved by this co-
administration, one can suggest possible reduction in the
dose of diclofenac in the future practice which may be
useful to achieve the desired efﬁcacy and yet also avoid
its well-known gastric toxicities such as ulceration and
subsequent hemorrhage [37–40].
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